ACLARIS THERAPEUTICS INC (ACRS)

Company Profile

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 91 full-time employees. The company went IPO on 2015-10-07. The firm has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The firm's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The firm's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.

Company Info

ACLARIS THERAPEUTICS INC

701 Lee Road, Suite 103

Wayne PENNSYLVANIA 19087

P: 14843247933

CEO: Neal Walker

Employees: 91

Website: https://www.aclaristx.com/